| Subject: | FDA Announces Recall Of One Lot Of Propafenone HCL 225 mg Tablets |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 25 Mar 2009 - 11:00 am |
| The Food and Drug Administration (FDA) and Watson Pharmaceuticals have notified healthcare professionals and patients of a recall of Propafenone HCL 225 mg tablets, a drug product used to treat cardiac arrhythmias. The drug is being recalled because some tablets may contain slightly higher levels of the active ingredient than specified. Because it has a narrow therapeutic index, some patients who are particularly sensitive to small variations in dose may experience potentially serious side... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
